Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Rationale

Immunotherapy applying ex vivo generated and tumor antigen-loaded dendritic cells (DC) has now successfully been introduced in the clinic. A limited, but consistent, number of objective immunological and clinical responses have been observed. Most of the successful results have been observed in patients with minimal residual disease, rather than patients with advanced metastatic disease. Moreover, the investigators' preliminary results show that presence of tumor epitope specific T cells in biopsies taken from delayed type hypersensitivity (DTH) reaction sites highly correlates with prolonged progression free survival (PFS).

Within uveal melanoma patients, a group with high risk of metastatic disease can be identified on basis of tumor specific genetic changes in loss of chromosome 3.

At present no standard adjuvant or systemic treatment is available. Applying DC-based immunotherapy in this group of high risk patients might reduce the risk of recurrence without interference in the current treatment guidelines.
2. Objectives

In this joint clinical study of Radboud University Nijmegen Medical Centre (RUNMC) and Rotterdam Eye Hospital, the investigators aim to determine the in vivo immunological response induced in high risk uveal melanoma patients vaccinated with mRNA-transfected DC.
3. Study design

This study is an open label non-randomized phase II intervention study.
4. Study population

The investigators' study population consists of HLA-A2 positive patients with a high risk uveal melanoma with proven expression of melanoma associated antigens tyrosinase and/or gp100.
5. Main study endpoints

This is an exploratory study aiming to demonstrate proof of principle. The first study endpoints are in vivo immunological response induced in high risk uveal melanoma patients vaccinated with mRNA-transfected DC, administered i.v./i.d. and toxicity. Secondary study endpoints are progression free survival, overall survival, and toxicity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients

NCT00243529

Melanoma Stage III or IV

COMPLETED PHASE1/PHASE2

Melanoma Patients Immunized with Natural DenDritic Cells

NCT02993315

Melanoma (Skin)

COMPLETED PHASE3

Dendritic Cell Based Therapy of Malignant Melanoma

NCT00197912

Advanced Melanoma

COMPLETED PHASE1/PHASE2

Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection

NCT00243594

Melanoma Stage III or IV

COMPLETED PHASE1/PHASE2

Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients

NCT00847106

Melanoma

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uveal Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dendritic cell vaccination

HLA-A2.1 positive patient will receive 3 biweekly intradermal/intravenous vaccination with autologous mRNA transfected mature dendritic cells, followed by a DTH skin test for monitoring purposes. One such cycle is repeated every 6 months if no signs of progression, up to a total of 3 cycles.

Group Type EXPERIMENTAL

autologous dendritic cells electroporated with mRNA

Intervention Type BIOLOGICAL

Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.

control arm

For comparison, HLA-A2.1 negative patients will be monitored for clinical response (secondary endpoint).

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

autologous dendritic cells electroporated with mRNA

Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histological documented uveal melanoma
* HLA-A2.1 phenotype (intervention arm)
* non-HLA-A2.1 phenotype (control arm)
* melanoma expressing gp100 and/or tyrosinase
* high risk genetic profile (loss of chromosome 3) determined by FISH
* interval since local treatment of uveal melanoma \< 12 months
* no signs of liver metastasis determined by diagnostic CT-abdomen
* normal serum LDH
* no signs of cerebral metastases
* bilirubin \< 25 micromol/l
* WHO performance scale 0-1
* age 18-75 years
* written informed consent
* expected adequacy of followup
* no pregnant or lactating women

Exclusion Criteria

* history of second malignancy, except adequately treated basal cell carcinoma
* serious active infections
* autoimmune disease or organ allografts
* concomitant use of immunosuppressive drugs
* known allergy to shell-fish

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No